Latest Australian Taxation News

State Gas Limited has decided against proceeding with the sale of its High Density Natural Gas Pilot Plant after failing to finalise terms, while its R&D tax incentive claim remains under extended review by the ATO.

BlackRock Investment Management (Australia) Limited has updated its estimated cash distributions for two key Australian iShares ETFs, with payments scheduled for mid-April 2026. Investors are reminded to update their details and complete tax certifications to ensure smooth dividend receipt.

BlackRock Investment Management (Australia) Limited has announced estimated cash distributions for a suite of Australian domiciled iShares ETFs, outlining key dates and participation details for investors.

Adelong Gold Limited has received a $1.17 million tax indemnity claim linked to alleged fraudulent GST reporting at Challenger Mines, which it plans to dispute. The claim stems from activities predating the current management team.

Resonance Health has received a $732,851 refund from the Australian Taxation Office, reflecting its FY2025 R&D tax incentive claim net of income tax payable. This cash inflow strengthens the company’s financial position ahead of its March quarterly report.

FAR Limited has agreed on a provisional US$23.7 million contingent payment from Woodside Energy tied to the Sangomar Project, prompting a proposed capital return of A$32.3 million to shareholders.

Janus Electric has locked in a $2.75 million R&D finance facility, strengthening its cash position to push forward with its zero-emission transport innovations. This strategic funding avoids shareholder dilution while supporting ongoing technology development.

Chimeric Therapeutics has secured a $1.785 million advance against its anticipated FY26 Research and Development Tax Incentive to bolster its clinical trial pipeline and working capital.

Hydrix Limited reported a 14% revenue decline and a sharp increase in net loss for H1 2026, raising concerns about its financial stability despite securing a major contract.

Careteq Limited reported a widening half-year loss with revenues down 18%, announcing plans to sell its Embedded Health Solutions business to strengthen its balance sheet and focus on its HMR Referral platform.

Percheron Therapeutics reports a 64% reduction in half-year losses to $3.1 million, driven by progress in its licensed immuno-oncology drug HMBD-002 and a strategic pivot away from discontinued assets.

Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.